LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Kodu・Aktsiate loetelu・Ovid therapeutics Inc

Ovid therapeutics Inc

Suletud

SektorTervishoid

2.47 1.65

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

2.4

Max

2.51

Põhinäitajad
By Trading Economics
Sissetulek	-27M -17M
Müük	586K 718K
Aktsiakasum	-0.125
Kasumimarginaal	-2,366.017
Töötajad	23
EBITDA	-5.5M -18M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+118.44% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	12. aug 2026

Turustatistika
By TradingEconomics
Turukapital	-25M 458M
Eelmine avamishind	0.82
Eelmine sulgemishind	2.47

Uudiste sentiment

By Acuity

50%

148 / 345 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

0.275 / 0.33 Toetus ja vastupanu

Ovid therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

22. mai 2026, 16:33 UTC

Tulu

Suurimad hinnamuutused turgudel

Webull Shares Slide on 1Q Loss, Soaring Costs

22. mai 2026, 21:10 UTC

Tulu

These Stocks Are Today's Movers: Dell, Apple, IBM, Estée Lauder, Futu, Rocket Lab, Workday, and More -- Barrons.com

22. mai 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

22. mai 2026, 20:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Financial Services Roundup: Market Talk

22. mai 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

22. mai 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

22. mai 2026, 19:47 UTC

Tulu

Nvidia Has a Plan to Get the Stock Moving Again -- Barrons.com

22. mai 2026, 19:17 UTC

Market Talk

U.S. Natural Gas Retreats As Weather Outlook Cools -- Market Talk

22. mai 2026, 19:10 UTC

Market Talk

Oil Futures Edge Up Ahead of U.S. Long Weekend -- Market Talk

22. mai 2026, 18:54 UTC

Market Talk

Global Equities Roundup: Market Talk

22. mai 2026, 18:54 UTC

Market Talk

Kroger Seen Narrowing Pricing Gap Versus Walmart -- Market Talk

22. mai 2026, 18:38 UTC

Market Talk

Canada's Population Slowdown Hits Demand for Consumer Companies -- Market Talk

22. mai 2026, 18:35 UTC

Omandamised, ülevõtmised, äriostud

IMAX Might Be Exploring a Sale. Who Could Be Buying. -- Barrons.com

22. mai 2026, 18:09 UTC

Market Talk

Centralized Crypto Lending Slows in 1Q -- Market Talk

22. mai 2026, 17:58 UTC

Market Talk

U.S. Oil Rig Count Shows Signs of Picking Up -- Market Talk

22. mai 2026, 17:54 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

22. mai 2026, 17:54 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

22. mai 2026, 17:54 UTC

Market Talk

Canada Minister May Be Distancing From Online-Streaming Order -- Market Talk

22. mai 2026, 17:03 UTC

Market Talk

Canada Spending Obligations on Streamers Is More Severe Beneath Surface -- Market Talk

22. mai 2026, 16:54 UTC

Market Talk

Crypto Spot Volumes Fall 14% in April -- Market Talk

22. mai 2026, 16:20 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Financial Services Roundup: Market Talk

22. mai 2026, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

22. mai 2026, 16:20 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

22. mai 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

22. mai 2026, 16:16 UTC

Market Talk

TSX Growth Driven Almost Entirely by Materials Sector -- Market Talk

22. mai 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

22. mai 2026, 15:55 UTC

Market Talk

Trump Admin Grants Reinforce IBM's Quantum Computing Leadership -- Market Talk

22. mai 2026, 15:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

22. mai 2026, 15:42 UTC

Market Talk

Oil Continues as Leading Indicator for All Markets -- Market Talk

22. mai 2026, 15:35 UTC

Market Talk

Gas Prices May Limit Spread of Inflationary Pressures in Canada -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Ovid therapeutics Inc Prognoos

Hinnasiht

By TipRanks

118.44% tõus

12 kuu keskmine prognoos

Keskmine 5.33 USD 118.44%

Kõrge 7 USD

Madal 4 USD

Põhineb 8 Wall Streeti analüütiku instrumendi Ovid therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

8 ratings

Osta

Hoia

Müü

Põhineb 8 analüütiku instrumendi Ovid therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.275 / 0.33Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There is one bearish event.

Sentiment

By Acuity

148 / 345 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Ovid therapeutics Inc

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.